Quick Takeaways:
- Genflow Biosciences will present full results from its SLAB canine ageing trial at the Animal Longevity Summit in Toronto, following completion of the study in elderly beagles evaluating GF-1004 for healthspan and sarcopenia.
- The company reported that GF-1004 was safe and well tolerated, with the study generating data on physical function and healthspan. Detailed findings will be presented Friday and are being prepared for peer-reviewed publication.
- Genflow is also in discussions with leading animal health companies while advancing its glaucoma program and liver disease research. The company noted that additional funding will be required to support its ongoing programs.
Why It Matters?
Presenting full SLAB trial data for GF‑1004 (a SIRT6‑based gene therapy) positions Genflow to seek an animal‑health licensing or co‑development deal in a fast‑growing pet longevity/sarcopenia niche. If the results show meaningful improvements in muscle function/healthspan with a clean safety profile, they could validate a first‑in‑class canine ageing therapeutic and support a premium, chronic‑use product.
Source: Yahoo Finance
